Literature DB >> 6322683

Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.

T Y Ti, L Fortin, J H Kreeft, D S East, R I Ogilvie, P J Somerville.   

Abstract

The kinetic disposition of a single intravenous dose of ceftriaxone (250 to 665 mg) was studied in six normal subjects and nine patients with renal insufficiency and normal hepatic function. In normal subjects, ceftriaxone was eliminated with a t1/2 beta of 5.2 h (range, 4.1 to 5.8). The total body clearance (Qb) was 13.5 ml/kg per h (range, 8.4 to 23.3), and renal clearance was 8.3 ml/kg per h (range, 5.8 to 13.3). In patients with severe renal insufficiency requiring peritoneal or hemodialysis, the mean t1/2 beta was prolonged to 13.4 h (range, 7.7 to 15.8) and the mean Qb was reduced to 6.9 ml/kg per h (range, 3.4 to 12.8). The apparent volumes of distribution (Vc and Vss) were not different from those determined in normal subjects. Peritoneal dialysis did not remove ceftriaxone. The dialysate of three patients on continuous peritoneal dialysis did not contain any measureable ceftriaxone, and the kinetic disposition in these patients was similar to the hemodialysis patients between their dialysis treatment. During a 4-h hemodialysis session, the total body clearance of ceftriaxone was reduced, perhaps secondary to a decrease in hepatic blood flow induced by the hemodialysis procedure. After a 12- or 24-h dose regimen, predicted trough concentrations of ceftriaxone in plasma at steady state derived from kinetic data generated from the study and assuming linear pharmacokinetic behavior were well above the minimum inhibitory concentrations of most sensitive bacteria, suggesting the feasibility of a once-a-day dosage regimen especially for patients with severe renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322683      PMCID: PMC185440          DOI: 10.1128/AAC.25.1.83

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  A study of the relationship between dose and pharmacokinetics of ceftriaxone.

Authors:  C D Findlay; R M Brown; J E Allcock; P A Lowe; R Wise
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

2.  A pharmacokinetic and tolerance study of Ro13-9904, a new cephalosporin antibiotic.

Authors:  M E Pickup; H A Bird; J R Lowe; L Lees; V Wright
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

3.  Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.

Authors:  A A Pollock; P E Tee; I H Patel; J Spicehandler; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

4.  Multiple intravenous dose pharmacokinetics of ceftriaxone in man.

Authors:  I H Patel; K Miller; R Weinfeld; J Spicehandler
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

5.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

6.  Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

Authors:  K Stoeckel; P J McNamara; R Brandt; H Plozza-Nottebrock; W H Ziegler
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

7.  Efficacy of ceftriaxone in serious bacterial infections.

Authors:  J S Epstein; S M Hasselquist; G L Simon
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

8.  Efficacy of a twelve-hourly ceftriaxone regimen in the treatment of serious bacterial infections.

Authors:  M J Maslow; J F Levine; A A Pollock; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

9.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

10.  Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion.

Authors:  K M Pizzella; M C Moore; R W Schultz; J Walshe; J J Schentag
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

  10 in total
  12 in total

Review 1.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 2.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 4.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 5.  Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.

Authors:  E Strehl; F Kees
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 6.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

7.  Ceftriaxone pharmacokinetics during peritoneal dialysis.

Authors:  J R Koup; E Keller; H Neumann; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vinçon; M Couzineau; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients.

Authors:  R Van Dalen; T B Vree; I M Baars
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

10.  Daily variations in ceftriaxone pharmacokinetics in rats.

Authors:  M Rebuelto; L Ambros; M Rubio
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.